Dr. Zhang on the Impact of the LATITUDE Study in Prostate Cancer

Video

Tian Zhang, MD, a medical instructor in the Department of Medicine, Duke University School of Medicine, discusses the impact of the LATITUDE study in prostate cancer.

Tian Zhang, MD, a medical instructor in the Department of Medicine, Duke University School of Medicine, discusses the impact of the LATITUDE study in prostate cancer.

Median progression-free survival and overall survival were both markedly improved with the addition of abiraterone acetate (Zytiga) to standard androgen-deprivation therapy (ADT) compared with ADT alone in patients with newly diagnosed, high-risk, metastatic prostate cancer.

Related Videos
Eduardo Sotomayor, MD
James Knight, MD
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine
Matthew Galsky, MD, professor of medicine, Hematology and Medical Oncology, director, Genitourinary Medical Oncology, codirector, Center of Excellence for Bladder Cancer, associate director, Translational Research, The Tisch Cancer Institute of Mount Sinai
Daneng Li, MD
Andre Goy, MD
Efrat Dotan, MD
Rachid Baz, MD, section head, Myeloma, Department of Malignant Hematology, Moffitt Cancer Center; co-director, Pentecost Family Myeloma Research Center
Marijo Bilusic, MD, PhD, GU site disease group lead, GU SDD medical oncology lead, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
A panel of 5 experts on renal cell carcinoma